Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA
Links:
Treatment of Pyoderma Gangrenosum With Vilobelimab
https://buff.ly/3VL5Rei
Jun-28-2024
